JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced ...
Key secondary endpoint includes superiority of oral step-down treatment with MAT2203 vs. AmBisome® (liposomal amphotericin B) for treatment-related toxicities leading to changes in treatment ...
PARIS--(BUSINESS WIRE)--Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, today announced the outcome of its regulatory ...
In this review published in The Lancet, researchers performed a double-blinded, phase III randomized trial to gather safety and immunogenicity data for a live-attenuated vaccine (LAV) candidate ...
Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...
- Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status The planned Phase 3 study will be a ...
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial [1], which has recruited and dosed its target 286 th adult patient The ACTION3 Phase 3 trial explores the efficacy and ...
(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback